Clinical trialNCT00262067UnknownPhase 3Interventional

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

SponsorGenentech, Inc.Enrollment1,237Metastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Leonardo Faoro, MD
Genentech, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

92 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Facility name not stated
Geelong, Australia
Facility name not stated
Malvern, Australia
Facility name not stated
Melbourne, Australia
Facility name not stated
Perth, Australia
Facility name not stated
Southport, Australia
Facility name not stated
Wahroonga, Australia
Facility name not stated
Waratah, Australia
Facility name not stated
Wollongong, Australia

Brazil

Facility name not stated
Porto Alegre, Brazil
Facility name not stated
Rio de Janeiro, Brazil
Facility name not stated
Salvador, Brazil
Facility name not stated
Santo André, Brazil
Facility name not stated
São Paulo, Brazil

Canada

Facility name not stated
Winnipeg, Manitoba, Canada
Facility name not stated
Montreal, Quebec, Canada
Facility name not stated
Montreal, Quebec, Canada

France

Facility name not stated
Marseille, France
Facility name not stated
Paris, France
Facility name not stated
Reims, France
Facility name not stated
Saint-Herblain, France
Facility name not stated
Strasbourg, France

Greece

Facility name not stated
Athens, Greece
Facility name not stated
Chania, Greece
Facility name not stated
Heraklion, Greece
Facility name not stated
Pátrai, Greece
Facility name not stated
Thessaloniki, Greece

Guatemala

Facility name not stated
Guatemala City, Guatemala

Mexico

Facility name not stated
Acapulco, Mexico
Facility name not stated
Aguascalientes, Mexico
Facility name not stated
Monterrey, Mexico
Facility name not stated
Monterrey, Mexico
Facility name not stated
Mérida, Mexico

Netherlands

Facility name not stated
Amstelveen, Netherlands
Facility name not stated
Apeldoorn, Netherlands
Facility name not stated
Delft, Netherlands

Norway

Facility name not stated
Oslo, Norway
Facility name not stated
Oslo, Norway

Panama

Facility name not stated
Panama City, Panama

Peru

Facility name not stated
Callao, Peru

Philippines

Facility name not stated
Quezon City, Philippines

52 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Chemotherapy →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2005
Primary completion: 31 Jul 2008
Completion: 31 Dec 2013
Last update posted: 13 Dec 2013
Registered enrollment: 1,237
Registry id: NCT00262067

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.